Shares of AntriaBio (OTCQB: ANTB) are 10% lower in morning trade after the biopharmaceutical company said it has filed an Investigational New Drug (IND) application with the FDA for AB101, the company’s once-weekly basal insulin for patients with diabetes mellitus. AntriaBio said it intends to subsequently initiate a phase 1 first-in-human clinical study to assess the safety and tolerability, pharmacokinetics and time-action profile of single ascending doses of AB101, administered to subjects with Type 1 diabetes mellitus.
To view the full press release, visit: http://nnw.fm/1oHbk
About AntriaBio, Inc.
AntriaBio is a patient-centric biopharmaceutical growth company specializing in the development of innovative drug therapies for patients with diabetes and metabolic diseases. AntriaBio’s lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a >$10 billion market where the current standard of care is a once-daily basal insulin injection. For more information visit: www.antriabio.com
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer